Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Amgevita HCF 40mg/0.4ml inj pre-filled pens
1001030S0BCAFAD
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | 1 |
|
Amgevita 20mg/0.4ml inj pre-filled syringes
1001030S0BCACAI
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 40mg/0.8ml inj pre-filled syringes
1001030S0BCAAAA
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 40mg/0.8ml solution for injection pre-filled pens
1001030S0BCABAB
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 20mg/0.2ml inj pre-filled syringes
1001030S0BCAHAF
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 40mg/0.4ml inj pre-filled syringes
1001030S0BCAGAE
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 80mg/0.8ml inj pre-filled pens
1001030S0BCADAH
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 80mg/0.8ml inj pre-filled syringes
1001030S0BCAEAG
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.